Product Name
LITAF, siRNA
Full Product Name
LITAF siRNA (Human)
Product Synonym Names
PIG7; SIMPLE; Lipopolysaccharide-induced tumor necrosis factor-alpha factor; LPS-induced TNF-alpha factor; Small integral membrane protein of lysosome/late endosome; p53-induced gene 7 protein
Product Gene Name
LITAF sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q99732
Specificity
LITAF siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human LITAF gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of LITAF sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
LITAF sirna
siRNA to inhibit LITAF expression using RNA interference
Applications Tested/Suitable for LITAF sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for LITAF. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001129944.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001136472.1
[Other Products]
UniProt Primary Accession #
Q99732
[Other Products]
UniProt Secondary Accession #
Q05DW0; Q9C0L6; D3DUG1; G5E9K0[Other Products]
UniProt Related Accession #
Q99732[Other Products]
Molecular Weight
15,824 Da
NCBI Official Full Name
lipopolysaccharide-induced tumor necrosis factor-alpha factor isoform 1
NCBI Official Synonym Full Names
lipopolysaccharide-induced TNF factor
NCBI Official Symbol
LITAF??[Similar Products]
NCBI Official Synonym Symbols
PIG7; SIMPLE; TP53I7
??[Similar Products]
NCBI Protein Information
lipopolysaccharide-induced tumor necrosis factor-alpha factor
UniProt Protein Name
Lipopolysaccharide-induced tumor necrosis factor-alpha factor
UniProt Synonym Protein Names
Small integral membrane protein of lysosome/late endosome; p53-induced gene 7 protein
Protein Family
Lipopolysaccharide-induced tumor necrosis factor-alpha factor
UniProt Gene Name
LITAF??[Similar Products]
UniProt Synonym Gene Names
PIG7; SIMPLE; LPS-induced TNF-alpha factor??[Similar Products]
UniProt Entry Name
LITAF_HUMAN
NCBI Summary for LITAF
Lipopolysaccharide is a potent stimulator of monocytes and macrophages, causing secretion of tumor necrosis factor-alpha (TNF-alpha) and other inflammatory mediators. This gene encodes lipopolysaccharide-induced TNF-alpha factor, which is a DNA-binding protein and can mediate the TNF-alpha expression by direct binding to the promoter region of the TNF-alpha gene. The transcription of this gene is induced by tumor suppressor p53 and has been implicated in the p53-induced apoptotic pathway. Mutations in this gene cause Charcot-Marie-Tooth disease type 1C (CMT1C) and may be involved in the carcinogenesis of extramammary Paget's disease (EMPD). Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Dec 2014]
UniProt Comments for LITAF
LITAF: Probable role in regulating transcription of specific genes. May regulate through NFKB1 the expression of the CCL2/MCP-1 chemokine. May play a role in tumor necrosis factor alpha (TNF- alpha) gene expression. Interacts with NEDD4. Interacts with WWOX. Isoform 2 may interact with STAT6. By bacterial lipopolysaccharides (LPS) or p53/TP53. In monocytes by the Bacillus Calmette-Guerin (BCG). Ubiquitously and abundantly expressed. Expressed predominantly in the placenta, peripheral blood leukocytes, lymph nodes and spleen. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Transcription factor; Oncoprotein
Chromosomal Location of Human Ortholog: 16p13.13
Cellular Component: nucleoplasm; Golgi apparatus; intracellular membrane-bound organelle; lysosomal membrane; cytoplasm; plasma membrane
Molecular Function: protein binding; signal transducer activity; WW domain binding
Biological Process: regulation of transcription from RNA polymerase II promoter; positive regulation of I-kappaB kinase/NF-kappaB cascade; transcription, DNA-dependent; apoptosis; negative regulation of NF-kappaB import into nucleus; signal transduction; aging; regulation of cytokine production
Disease: Charcot-marie-tooth Disease, Demyelinating, Type 1c
Research Articles on LITAF
1. The results of this study findings confirm that the genetic analysis of LITAF/SIMPLE should be considered for the diagnostic flow-chart of CMT1 patient, especially when nerve conduction studies show the presence of conduction blocks.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
